{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:29:57Z","timestamp":1790206197374,"version":"4.1.0"},"reference-count":48,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,2,10]],"date-time":"2014-02-10T00:00:00Z","timestamp":1391990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["M01 RR000865, K24 AI56933, P30 AG028748, T32 MH080634"],"award-info":[{"award-number":["M01 RR000865, K24 AI56933, P30 AG028748, T32 MH080634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000085","name":"Ontario HIV Treatment Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000085","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Canada, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Soluble\n                      <jats:styled-content style=\"fixed-case\">CD14<\/jats:styled-content>\n                      (\n                      <jats:styled-content style=\"fixed-case\">sCD14<\/jats:styled-content>\n                      ) is a monocyte activation marker associated with increased mortality in\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      infection. We assessed 48\u2010week changes in\n                      <jats:styled-content style=\"fixed-case\">sCD14<\/jats:styled-content>\n                      and other inflammatory biomarkers in virologically suppressed,\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      \u2010infected women switching to raltegravir (\n                      <jats:styled-content style=\"fixed-case\">RAL<\/jats:styled-content>\n                      ) from a protease inhibitor (\n                      <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                      ) or nonnucleoside reverse transcriptase inhibitor (\n                      <jats:styled-content style=\"fixed-case\">NNRTI<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      \u2010infected women with central adiposity and\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      \u20101\n                      <jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content>\n                      &lt;\u200950\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      \u20101\n                      <jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content>\n                      copies\/mL continued their thymidine\u2010sparing nucleoside reverse transcriptase inhibitor (\n                      <jats:styled-content style=\"fixed-case\">NRTI<\/jats:styled-content>\n                      ) backbone and were randomized to switch to open\u2010label\n                      <jats:styled-content style=\"fixed-case\">RAL<\/jats:styled-content>\n                      at week 0 (immediate) or 24 (delayed). In an exploratory analysis, inflammatory biomarkers were measured on stored fasting plasma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 37 evaluable subjects, 78% were non\u2010\n                      <jats:styled-content style=\"fixed-case\">W<\/jats:styled-content>\n                      hite; the median age was 43 years, the median body mass index (\n                      <jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>\n                      ) was 32\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and the median\n                      <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                      4 count was 558\u2009cells\/\u03bcL. At baseline, biomarker values were similar between groups. After 24 weeks, median\n                      <jats:styled-content style=\"fixed-case\">sCD14<\/jats:styled-content>\n                      significantly declined in subjects switching to\n                      <jats:styled-content style=\"fixed-case\">RAL<\/jats:styled-content>\n                      [\u221221% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001)\n                      <jats:italic>vs.<\/jats:italic>\n                      \u2005\n                      <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">NNRTI<\/jats:styled-content>\n                      \u22125% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.49); between\u2010group\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01]. After 48 weeks, immediate\u2010switch subjects maintained this decline and delayed\u2010switch subjects experienced a similar decline following the switch to\n                      <jats:styled-content style=\"fixed-case\">RAL<\/jats:styled-content>\n                      (\u221210%; within\u2010group\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Immediate\u2010switch subjects also experienced an initial increase in tumour necrosis factor (\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      )\u2010\u03b1 that was neither maintained after 48 weeks nor seen in delayed\u2010switch subjects. After adjustment for multiple testing, only declines in\n                      <jats:styled-content style=\"fixed-case\">sCD14<\/jats:styled-content>\n                      remained significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In this randomized trial of women with central adiposity, a switch to\n                      <jats:styled-content style=\"fixed-case\">RAL<\/jats:styled-content>\n                      from a\n                      <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                      or\n                      <jats:styled-content style=\"fixed-case\">NNRTI<\/jats:styled-content>\n                      was associated with a statistically significant decline in\n                      <jats:styled-content style=\"fixed-case\">sCD14<\/jats:styled-content>\n                      . Further studies are needed to determine whether integrase inhibitors have improved monocyte activation profiles compared with\n                      <jats:styled-content style=\"fixed-case\">PIs<\/jats:styled-content>\n                      and\/or\n                      <jats:styled-content style=\"fixed-case\">NNRTIs<\/jats:styled-content>\n                      , and whether measured differences between antiretroviral agents translate to demonstrable clinical benefit.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.12128","type":"journal-article","created":{"date-parts":[[2014,2,10]],"date-time":"2014-02-10T01:06:45Z","timestamp":1391994405000},"page":"431-441","source":"Crossref","is-referenced-by-count":37,"title":["Switch to raltegravir decreases soluble\n                    <scp>CD14<\/scp>\n                    in virologically suppressed overweight women: the\n                    <scp>W<\/scp>\n                    omen,\n                    <scp>I<\/scp>\n                    ntegrase and\n                    <scp>F<\/scp>\n                    at\n                    <scp>A<\/scp>\n                    ccumulation\n                    <scp>T<\/scp>\n                    rial"],"prefix":"10.1111","volume":"15","author":[{"given":"JE","family":"Lake","sequence":"first","affiliation":[{"name":"Department of Medicine University of California  Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GA","family":"McComsey","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Medicine Case Western Reserve University  Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hulgan","sequence":"additional","affiliation":[{"name":"Department of Medicine Vanderbilt University  Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CA","family":"Wanke","sequence":"additional","affiliation":[{"name":"Department of Medicine Tufts University  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mangili","sequence":"additional","affiliation":[{"name":"Department of Medicine Tufts University  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SL","family":"Walmsley","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SA","family":"Stramotas","sequence":"additional","affiliation":[{"name":"University of California  Riverside CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Tracy","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Vermont  Burlington VT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JS","family":"Currier","sequence":"additional","affiliation":[{"name":"Department of Medicine University of California  Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181f7f61a"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0633"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0034"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/652749"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328354f4fb"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050203"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq118"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir134"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.453266"},{"key":"e_1_2_6_11_1","first-page":"79","article-title":"Structure\u2010function analysis of soluble and membrane\u2010bound CD14","volume":"397","author":"Kirkland TN","year":"1998","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065211"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit025"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328339e228"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018580"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis708"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir989"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2012.06.008"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2012.0135"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283546595"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12015"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis545"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046073"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.6698"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042624"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182237e54"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32836010bd"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002516"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835f2b49"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit453"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2111"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/650749"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir721"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283584521"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031990"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir559"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328359f20f"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62041-9"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-012-0305-5"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1159\/000339044"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-012-1306-y"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(03)00096-1"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055038"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328359f29c"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055279"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474-9726.2012.00851.x"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328351f756"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04284.x"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2013.0016"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12128","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:04:54Z","timestamp":1696327494000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,10]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/hiv.12128"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12128","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,10]]}}}